Does Cosentyx Cause Thrush?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, lists oral candidiasis (thrush) as a possible side effect in its prescribing information. Clinical trials reported it in 1-3% of patients, higher than placebo rates of under 1%. It's linked to immune suppression affecting mucosal defenses against Candida yeast.[1]
How Common Is Thrush with Cosentyx?
In pivotal trials like FUTURE 1-5 for psoriatic arthritis and MEASURE for ankylosing spondylitis:
- Oral candidiasis occurred in 1.9% of Cosentyx users vs. 0.8% on placebo.
- Rates rose slightly with higher doses (300 mg subcutaneous).
Post-marketing data shows similar low incidence, often mild and resolving without stopping treatment.[1][2]
Why Does It Happen?
IL-17 blockade impairs neutrophil recruitment and antifungal responses at skin/mucosal sites. Thrush risk increases in patients with prior infections, diabetes, or steroid use. It's not a direct cause for most users but a class effect shared with other IL-17 inhibitors like Taltz (ixekizumab), where rates hit 2-7%.[3]
What Do Patients Report?
Real-world forums (e.g., Drugs.com reviews, Reddit) mention thrush in 5-10% of Cosentyx users, often after months of use. Symptoms include white mouth patches, soreness, or taste changes. Many resolve with antifungals like nystatin; some switch drugs.[4]
How to Manage or Prevent Thrush on Cosentyx?
- Monitor mouth weekly; treat early with OTC rinses or prescription antifungals.
- Good oral hygiene, probiotics, and avoiding sugars help.
- Doctors may prescribe prophylactic fluconazole for high-risk cases.
Discontinue if severe or recurrent.[1]
Compared to Other Biologics
| Drug | Thrush Risk | Notes |
|------|-------------|--------|
| Cosentyx | 1-3% | Lowest in IL-17 class |
| Taltz | 2-7% | Higher trial rates |
| Stelara (ustekinumab) | <1% | IL-12/23; minimal |
| Humira (adalimumab) | 0.5-1% | TNF; rare |
Thrush is rarer with TNF inhibitors but more common with IL-17/23 drugs.[3]
When to See a Doctor
Contact your provider if thrush persists >1 week, spreads, or includes fever/swallowing pain—could signal deeper infection. No black-box warning, but monitor in immunocompromised patients.[1]
[1]: Cosentyx Prescribing Information (Novartis, 2023)
[2]: FDA Adverse Event Reporting System (FAERS) data via Drugs.com
[3]: Comparative review in Journal of the American Academy of Dermatology (2022)
[4]: Patient reviews aggregated from Drugs.com (user rating 6.5/10, n=1,200+ as of 2024)